Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. insiders are currently net buyers of AVTE stock, showing bullish sentiment over the past 90 days. Executives have purchased $72.5M while selling $17.7M, resulting in a positive net flow of $54.8M. This buying activity represents 80% of total transaction volume.

Aerovate Therapeutics, Inc. has 19 active insiders who have filed SEC Form 4 transactions in the past 90 days. Rajeev M. Shah (Executive) leads with 5 transactions totaling $40.5M. Benjamin T. Dake (Executive) follows with 157 transactions worth $9.3M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Aerovate Therapeutics, Inc.'s current score of 80/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $72.5M in purchases versus $17.7M in sales.

The most recent insider transaction occurred on Aug 1, 2024, when T. Dake Benjamin (Executive) disposed of 1,507 shares at $0.00 per share for $0. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, AVTE insider trading sentiment is currently bullish with an Alignment Score of 80/100. The net insider flow of $54.8M reflects accumulation, with 80% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Aerovate Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At AVTE, we track all Form 4 filings—currently showing 424 transactions from 19 insiders over 90 days.

A 10b5-1 plan allows Aerovate Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At AVTE, approximately 70% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Aerovate Therapeutics, Inc. (AVTE) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 19 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Aerovate Therapeutics, Inc.'s current score of 80/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $72.5M in purchases versus $17.7M in sales over 90 days, resulting in a net flow of $54.8M.

SEC Form 4 filings are mandatory reports that Aerovate Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At AVTE, the most common type is "M" with 24 occurrences. The most recent Form 4 was filed on Aug 1, 2024 by T. Dake Benjamin.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Aerovate Therapeutics, Inc., approximately 70% of recent transactions are executed under 10b5-1 plans, while 30% appear to be discretionary trades. This high percentage suggests selling activity may be routine diversification.